Literature DB >> 15832032

Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT.

Soichiro Shimizu1, Haruo Hanyu, Hidekazu Kanetaka, Toshihiko Iwamoto, Kiyoshi Koizumi, Kimihiko Abe.   

Abstract

We compared regional cerebral blood flow (CBF) patterns in patients with dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) using single photon emission computed tomography (SPECT) and investigated the diagnostic utility of SPECT study in differentiating between DLB and AD. SPECT data on 20 patients with DLB and 75 patients with AD were analyzed using three-dimensional stereotactic surface projections. Regional CBF reduction was determined by quantitative analysis using stereotactic extraction estimation method. The DLB group showed a significant CBF reduction in the temporoparietal, frontal lobe and posterior cingulate, similar to the CBF pattern in the AD group, but regional CBF in the medial and lateral occipital lobes decreased significantly in patients with DLB compared with patients with AD. Receiver operating characteristic analysis revealed that regional CBF measurement of the medial occipital lobe, including the cuneus and lingual gyrus, yielded a sensitivity of 85% and a specificity of 85% in discriminating DLB from AD. Objective and quantitative CBF measurement in the medial occipital lobe may be useful in the clinical differentiation of DLB and AD. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2005        PMID: 15832032     DOI: 10.1159/000085070

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  18 in total

1.  Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease.

Authors:  Haruo Hanyu; Soichiro Shimizu; Kentaro Hirao; Hidekazu Kanetaka; Toshihiko Iwamoto; Taishiro Chikamori; Yasuhiro Usui; Akira Yamashina; Kiyoshi Koizumi; Kimihiko Abe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-11-22       Impact factor: 9.236

2.  Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

Authors:  C Wischik; R Staff
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

3.  Cerebrospinal fluid biomarkers for dementia with lewy bodies.

Authors:  Elizabeta B Mukaetova-Ladinska; Rachael Monteith; Elaine K Perry
Journal:  Int J Alzheimers Dis       Date:  2010-10-17

4.  Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies.

Authors:  Maja A A Binnewijzend; Joost P A Kuijer; Wiesje M van der Flier; Marije R Benedictus; Christiane M Möller; Yolande A L Pijnenburg; Afina W Lemstra; Niels D Prins; Mike P Wattjes; Bart N M van Berckel; Philip Scheltens; Frederik Barkhof
Journal:  Eur Radiol       Date:  2014-07-05       Impact factor: 5.315

5.  Differential diagnosis of dementia with Lewy Bodies and Alzheimer Disease using combined MR imaging and brain perfusion single-photon emission tomography.

Authors:  H Goto; K Ishii; T Uemura; N Miyamoto; T Yoshikawa; K Shimada; S Ohkawa
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-14       Impact factor: 3.825

6.  Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life.

Authors:  Montserrat Estorch; Valle Camacho; Pilar Paredes; Elisabet Rivera; Ato Rodríguez-Revuelto; Albert Flotats; Jaume Kulisevsky; Ignasi Carrio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-29       Impact factor: 9.236

Review 7.  Dementia with Lewy bodies.

Authors:  Tanis J Ferman; Bradley F Boeve
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

8.  Multivariate spatial covariance analysis of 99mTc-exametazime SPECT images in dementia with Lewy bodies and Alzheimer's disease: utility in differential diagnosis.

Authors:  Sean J Colloby; John-Paul Taylor; Christopher M Davison; Jim J Lloyd; Michael J Firbank; Ian G McKeith; John T O'Brien
Journal:  J Cereb Blood Flow Metab       Date:  2013-01-30       Impact factor: 6.200

9.  Perfusion Imaging with SPECT in the Era of Pathophysiology-Based Biomarkers for Alzheimer's Disease.

Authors:  Markus Weih; Umüt Degirmenci; Sebastian Kreil; Piotr Lewczuk; Daniela Schmidt; Johannes Kornhuber; Torsten Kuwert
Journal:  Int J Alzheimers Dis       Date:  2010-12-15

Review 10.  Brain SPECT as a Biomarker of Neurodegeneration in Dementia in the Era of Molecular Imaging: Still a Valid Option?

Authors:  Rodolfo Ferrando; Andres Damian
Journal:  Front Neurol       Date:  2021-05-10       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.